Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy

Department of Pediatrics, Subdivision of Endocrinology, Sophia Children's Hospital, 3015 GJ Rotterdam, The Netherlands.
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 03/2002; 87(2):506-12. DOI: 10.1210/jcem.87.2.8202
Source: PubMed

ABSTRACT We studied bone mineral density (BMD), bone metabolism, and body composition in 47 children with central precocious puberty (n = 36) or early puberty (n = 11) before, during, and after cessation of GnRH agonist. Bone density and body composition were measured with dual energy x-ray absorptiometry and expressed as SD scores. Bone age and biochemical parameters of bone turnover were assessed. Measurements were performed at baseline, after 6 months, and on a yearly basis thereafter. Mean lumbar spine BMD SD scores for chronological age were significantly higher than zero at baseline and decreased during treatment. Lumbar spine bone mineral apparent density and total body BMD did not differ from normal at baseline and showed no significant changes during treatment. In contrast, BMD SD scores for bone age were significantly lower than zero at baseline and at cessation of therapy. Two years after therapy, bone mineral apparent density and BMD SD scores for bone age and chronological age did not differ from normal. Markers of bone turnover decreased during treatment, mainly in the first 6 months. Patients had increased percentage of fat and lean body mass at baseline. After an initial increase of percentage body fat during treatment, percentage body fat decreased and normalized within 1 yr after cessation of treatment. Our longitudinal analysis suggests that peak bone mass or body composition will not be impaired in patients with precocious or early puberty after GnRH agonist therapy.

Download full-text


Available from: Annemieke M Boot, Aug 05, 2015
  • Source
    • "There are reports of a decrease in bone density during the clinical evolution of precocious puberty. No differences were, however, found in the same individuals in adulthood when compared with those with normal pubertal development (Van der Sluis et al., 2002). SUMMARY This investigation examined the effects of pharmacologically induced precocious puberty on cranial growth in Wistar rats. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This investigation examined the effects of pharmacologically induced precocious puberty on cranial growth in Wistar rats. Forty-eight female newborn Wistar rats were divided into two groups: a control group (C) and an experimental group (E), with four subgroups of six animals each. The time interval from birth until sacrifice differed between the subgroups, and was set at 30, 60, 90, and 120 days. An intramuscular single dose (300 μg) of steroid hormone danazol was administered on day 5 after birth, as a means of inducing precocious puberty. Alizarin (2 mg/100 g) was administered to three animals in each subgroup three days prior to sacrifice. Body mass and dates corresponding to the beginning of the oestrous cycle were recorded. Craniometric measurements were undertaken. Histological analysis using light and fluorescence microscopy was then carried out to qualitatively and quantitatively evaluate the spheno-occipital synchondrosis and to visualize bone deposition patterns. The results were analysed with a Student's t-test and analysis of variance. Precocious puberty was effectively induced and differences between groups denoted an earlier maturation in the experimental rats. In qualitative analysis, a significant increase of total synchondrosis width was noted only in group E60, in comparison with C60, and an increase in the E90 subgroup cortical bone width compared with the C90 subgroup. Histomorphometrically, a statistical difference between total width values of subgroups E60 (434.3 μm) and C60 (323.5 μm) was detected. However, body mass and macroscopic measurements did not show statistically significant differences. An appropriate model for studying bone growth associated with precocious puberty in Wistar female rats was not achieved using steroid hormone danazol, when evaluated at 30 day intervals.
    The European Journal of Orthodontics 04/2012; 34(2):133-140. · 1.39 Impact Factor
  • Source
    • "GnRH agonists generally are tolerated well, but occasionally , an initial, temporary flare of GnRH activity can occur and result in transient advancement of secondary sexual characteristics and even vaginal bleeding. Initial concerns about long-term effects of GnRH agonists on bone mineral density have been alleviated [91], and although there are contradictory data [91] [92], it appears that GnRH agonist therapy does not lead to obesity beyond that predicted by baseline, pretreatment status. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Disorders of pubertal timing are common and challenging problems for pediatric endocrinologists. Early or late puberty can have immediate effects on a child's psychosocial well-being and may have long-term effects on adult stature. Much is known about the regulation of the hypothalamic-pituitary-gonadal axis, but the triggers of pubertal onset in the general population remain elusive. This article reviews recent data suggesting a possible shift in the age of pubertal onset; current knowledge regarding factors that regulate the onset of puberty; and the etiologies, diagnosis, and treatment of precocious and delayed puberty.
    Endocrinology & Metabolism Clinics of North America 10/2005; 34(3):617-41, ix. DOI:10.1016/j.ecl.2005.04.015 · 2.86 Impact Factor
  • Source
    • "Oostdijk et al., 1996) recorded BMI SD scores for chronological age of 1·7, 1·8 and 1·44 at the start and end of treatment and at final height, respectively, in 30 girls treated with Triptorelin for 3·4 years. Van der Sluis et al. (2002) looked at body composition in 20 children with CPP/EPP and found that both percentage body fat (measured by DXA) and BMI SDS for chronological age were significantly above average at baseline, increased during treatment and then decreased to below pretreatment levels by 2 years post-therapy. By contrast, a large cohort of 50 girls described by Heger et al. (1999) was markedly overweight, with a mean BMI SDS of 2·0 pretreatment and 1·7 at final height. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Following a successful clinical trial in 1996, the long-acting GnRH analogue goserelin (Zoladex LA 10.8 mg; Astra Zeneca) has been our preferred treatment for central early (CEP) or precocious puberty (CPP). However, some female patients have expressed concern about perceived weight gain during therapy and delay in the onset or resumption of menses on completion of therapy. The primary aim of this study was to investigate these concerns by determining the auxological parameters and timing of menarche or re-menarche in all girls with CEP/CPP who have completed a course of Zoladex LA treatment. The secondary aim was to assess auxological outcome in girls who have attained final height. Case records of all girls with idiopathic CEP/CPP or CEP/CPP secondary to CNS pathology treated with Zoladex LA since 1996 were reviewed. A total of 46 girls who have completed therapy were identified, of whom 11 had reached final height. measurements Height, weight and bone age (RUS (TW2) method) were measured before treatment, when Zoladex LA was stopped and at final height. Body mass index (BMI) was calculated as a clinical measure of body fatness. Pubertal status was assessed pre- and post-treatment by Tanner staging and pelvic ultrasonography. Timing of menarche or re-menarche following cessation of treatment was recorded. The mean (range) age of starting GnRH analogue therapy was 8.3 (1.8-10.5) years and the duration of treatment was 2.9 (0.7-8.9) years. Pre-treatment height was above average at 0.72 SD but had declined to 0.28 SD by the end of therapy. The 46 girls were heavier than average before treatment (Wt SDS 1.04) with no change in weight status on completion of therapy. Mean BMI SDS increased significantly from 0.93 to 1.2 during treatment, indicating that the girls became relatively fatter. Using recommended BMI cut-off values for defining overweight and obesity in children of the 85th and 95th centiles, 41% of the cohort were overweight and 28% were obese before treatment, rising to 59% and 39%, respectively, at the end of therapy. The average time interval to onset or resumption of menses after stopping treatment was 1.46 years (median 1.5, range 0.8-2.0 years). None of the following variables was found to be predictive of the time interval to menarche after completion of therapy: duration of treatment; chronological age; bone age; Tanner breast stage or uterine maturation at the end of treatment; the frequency of injections required to suppress puberty; or treatment with alternative GnRH analogue prior to Zoladex LA. Mean final height in 11 girls was 159.7 cm (-0.63 SD), close to the mean parental target height of 160.9 cm (-0.48 SD). Nine of the 11 girls (82%) attained final heights within or above their target range. In keeping with the whole cohort this subset of girls became fatter during treatment, although this difference was not statistically significant. However, they returned to their pretreatment size at final height (mean BMI SDS 1.18, 1.41 and 1.16 before, at the end of treatment and at final height, respectively). Our cohort of 46 girls treated with long-acting goserelin was already considerably overweight at the start of therapy and became fatter during treatment. However, adiposity appeared to return to pretreatment levels in the 11 girls followed up to final height. Most of the girls who have attained final height are within or above their expected target range. The relatively long time interval to menarche of 1.5 years after stopping treatment is unexplained but may reflect a residual suppressive effect on the hypothalamo-pituitary axis of this long-acting GnRH analogue. Anticipation of the timing of menarche has proved to be of value in planning when to stop therapy in girls in whom treatment is mainly for practical and/or psychological reasons.
    Clinical Endocrinology 12/2004; 61(5):626-34. DOI:10.1111/j.1365-2265.2004.02146.x · 3.35 Impact Factor
Show more